Compare Amgen, Inc. (AMGN) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Wix.Com Ltd — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Wix.Com Ltd trades at $50.39 (market cap $2.10B). The key difference: Amgen, Inc. is far larger — about 93.4× Wix.Com Ltd's market cap, and Amgen, Inc. pays a 2.77% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals.
| AMGN | WIX | |
|---|---|---|
Market Cap | $196.12B | $2.10B |
Sector | Health | Technology |
52-Week High | $388.16 | $184.24 |
52-Week Low | $271.18 | $40.43 |
Enterprise Value | $241.41B | $1.66B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Wix trades at $50.14, up 1.83% today, with a bearish technical signal despite recent earnings beats in Q3 and Q4 2025. Revenue grew to $1.99B in 2025, but net income margin remains negative at -1.97%. Recent news includes partnerships with Elavon and Microsoft, but multiple law firms are investigating potential securities fraud following a 27% stock drop in May 2026.
Analyst consensus is bullish with a $83.13 price target, but risks include ongoing fraud investigations, volatile cash flows, and negative shareholder equity. The stock faces headwinds from competitive pressures and execution risks despite strong revenue growth and institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
